LEP and non-small cell lung carcinoma: The authors showed that leptin secreted from bone marrow-derived stem cells through the activation of IGF1 signaling pathway induces resistance to erlotinib, an inhibitor of EGFR introduced into the first-line treatment for NSCLC patients [158].